ExodusPoint Capital Management’s Surgery Partners SGRY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-84,330
Closed -$1.82M 2013
2025
Q3
$1.82M Sell
84,330
-79,104
-48% -$1.76M 0.02% 765
2025
Q2
$3.63M Buy
163,434
+11,700
+8% +$260K 0.03% 517
2025
Q1
$3.6M Sell
151,734
-30,566
-17% -$723K 0.04% 517
2024
Q4
$3.86M Buy
182,300
+159,131
+687% +$4.18M 0.03% 518
2024
Q3
$747K Sell
23,169
-317,887
-93% -$9.39M ﹤0.01% 1062
2024
Q2
$8.11M Buy
341,056
+105,265
+45% +$2.7M 0.06% 297
2024
Q1
$7.03M Buy
+235,791
New +$7.38M 0.05% 282
2023
Q4
Sell
-19,773
Closed -$578K 1992
2023
Q3
$578K Buy
+19,773
New +$711K 0.01% 1187
2023
Q1
Sell
-18,450
Closed -$514K 2091
2022
Q4
$514K Sell
18,450
-79,401
-81% -$2.1M 0.01% 1162
2022
Q3
$2.29M Buy
+97,851
New +$3.12M 0.03% 745
2021
Q1
Sell
-16,264
Closed -$472K 2552
2020
Q4
$472K Buy
+16,264
New +$405K ﹤0.01% 1289
2019
Q4
Sell
-39,556
Closed -$292K 1848
2019
Q3
$292K Buy
+39,556
New +$283K 0.01% 892

Other funds holding SGRY

ExodusPoint Capital Management's SGRY Position: Q4 2025 in Review

ExodusPoint Capital Management sold out of Surgery Partners (SGRY) in Q4 2025, closing a stake of 84,330 shares — an estimated $1.82M sold.

ExodusPoint Capital Management first reported a position in SGRY in Q3 2019 and held it in 12 quarters. The position peaked at $8.11M in Q2 2024. 180 funds tracked by Wall St. Rank hold SGRY as of Q4 2025.

  • ExodusPoint Capital Management reported no remaining Surgery Partners position as of Q4 2025 after selling out during the quarter.
  • ExodusPoint Capital Management sold 84,330 Surgery Partners shares in Q4 2025, an estimated $1.82M.
  • ExodusPoint Capital Management first reported a position in Surgery Partners in Q3 2019 and held it in 12 quarters.
  • ExodusPoint Capital Management's Surgery Partners position peaked at $8.11M in Q2 2024.
  • 180 funds tracked by Wall St. Rank held Surgery Partners as of Q4 2025.

Based on ExodusPoint Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.